OTCMKTS:GBIM GlobeImmune Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GlobeImmune Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.17 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$0.17Now: $0.17▼$0.1750-Day Range$0.16MA: $0.32▼$0.5152-Week Range$0.06Now: $0.17▼$0.51VolumeN/AAverage Volume34,211 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABeta1.93 ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GlobeImmune. Previous Next 2.3 Community Rank Outperform VotesGlobeImmune has received 57 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGlobeImmune has received 69 “underperform” votes. (Add your “underperform” vote.)Community SentimentGlobeImmune has received 54.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GlobeImmune and other stocks. Vote “Outperform” if you believe GBIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBIM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGlobeImmune does not currently pay a dividend.Dividend GrowthGlobeImmune does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlobeImmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 23.50% of the stock of GlobeImmune is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GBIM Previous SymbolNASDAQ:GBIM CUSIPN/A CIK1245104 Webwww.globeimmune.com Phone303-625-2700Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees2 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable $0.17 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GBIM News and Ratings via Email Sign-up to receive the latest news and ratings for GBIM and its competitors with MarketBeat's FREE daily newsletter. GlobeImmune (OTCMKTS:GBIM) Frequently Asked Questions How has GlobeImmune's stock price been impacted by COVID-19? GlobeImmune's stock was trading at $0.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GBIM stock has increased by 72.0% and is now trading at $0.1720. View which stocks have been most impacted by COVID-19. How were GlobeImmune's earnings last quarter? GlobeImmune Inc (OTCMKTS:GBIM) posted its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter. View GlobeImmune's earnings history. Who are some of GlobeImmune's key competitors? Some companies that are related to GlobeImmune include Acusphere (ACUS), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE) and Diadexus (DDXSQ). View all competitors. What other stocks do shareholders of GlobeImmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP), Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tanker (NAT), Banro (BAA), PETROLEO BRASIL/ADR (PBR), Pengrowth Energy (PGH), Absolute Software (ABT) and Alacer Gold (ASR). Who are GlobeImmune's key executives? GlobeImmune's management team includes the following people: Mr. C. Jeffrey Dekker CPA, Pres, VP of Fin., Treasurer, Sec. and Director (Age 54)Dr. Richard C. Duke, Scientific Founder & Member of Scientific Advisory BoardDr. Donald Bellgrau, Scientific Founder & Chairman of The Scientific Advisory BoardMr. Thomas A. Keuer, Acting Head of Manufacturing Operations (Age 60)Dr. Allen L. Cohn M.D., Exec. Director Clinical Devel. (Age 61) What is GlobeImmune's stock symbol? GlobeImmune trades on the OTCMKTS under the ticker symbol "GBIM." How do I buy shares of GlobeImmune? Shares of GBIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GlobeImmune's stock price today? One share of GBIM stock can currently be purchased for approximately $0.17. What is GlobeImmune's official website? The official website for GlobeImmune is www.globeimmune.com. How can I contact GlobeImmune? GlobeImmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
